Drug Profile

APC 148

Alternative Names: APC-148

Latest Information Update: 27 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AdjuTec Pharma
Class Antibacterials
Mechanism of Action Beta lactamase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Gram-negative infections

Most Recent Events

10 Mar 2025 AdjuTec Pharma completes a phase I trial in Gram-negative infections (In volunteers) in Sweden (IV) (NCT06360640)
17 Dec 2024 AdjuTec Pharma announces intention to submit the regulatory applications to the US FDA and EMA for Gram negative infections in 2028 (AdjuTec Pharma website, December 2024)
17 Dec 2024 AdjuTec Pharma completes the pre-IND meeting with the US FDA prior to December 2024 (AdjuTec Pharma website, December 2024).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com